Skincalm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Skincalm

What is Skincalm? Overview and Quick Facts

Property Description
Active Ingredient Hydrocortisone (Cortisol)
Form Cream (Topical Dosage Form)
Pharmacological Class Corticosteroid (Glucocorticoid)
Potency Classification Weak (Group I) Topical Steroid
Origin Synthetic derivative of a natural hormone

What is Skincalm? Definition and Composition

Skincalm is a medicine intended for topical dermal application, characterized as a single-ingredient preparation containing the active ingredient, Hydrocortisone. This compound is chemically known as 17-hydroxycorticosterone and is the pharmaceutical term for Cortisol. The drug is primarily formulated as a pharmaceutical cream, designed to ensure localized delivery of the compound to the skin surface. As a therapeutic agent, Hydrocortisone is a synthetic derivative of the naturally produced human glucocorticoid hormone. Skincalm is positioned as an over-the-counter (OTC) option in many regions, differentiating it from stronger, prescription-only corticosteroid formulations.

Skincalm's Classification: A Topical Corticosteroid

Skincalm belongs to the pharmacological class of corticosteroids, specifically categorized as a glucocorticoid due to its targeted anti-inflammatory action. This class of medication is widely recognized for its ability to rapidly reduce inflammation and swelling associated with various skin irritations. The ATC designation D07AA02 further identifies it as a weak topical steroid, meaning it provides focused, mild modulation of localized skin irritation. This profile is appropriate for use in many non-severe, superficial skin concerns.

General Purpose: Anti-Inflammatory Action

The fundamental purpose of Skincalm is to provide rapid anti-inflammatory relief by directly intervening in the inflammatory cascade. The Hydrocortisone acts as a vasoconstrictor, reducing localized capillary blood flow and inhibiting the release of inflammatory mediators. This means the cream provides the crucial benefit of easing the physical signs of irritation, such as redness and swelling, along with the discomfort of persistent itching, a typical use scenario for this type of topical medicine.

What side effects are possible with Skincalm?

Possible Side Effects and Safety Information

The safety profile of Skincalm is defined by potential local skin reactions and the risk of systemic effects associated with improper use. Side effects are typically mild and localized, but users must be aware of serious, though rare, adverse reactions and specific usage restrictions.

Adverse Reactions and Safety Concerns Details
Local Skin Reactions May include thinning of the skin (atrophy), widening of blood vessels (telangiectasia), and stretch marks, particularly with prolonged or extensive use in sensitive areas or skin folds.
Serious Adverse Reactions Anaphylaxis is a very serious, but rare, allergic reaction; signs include swelling of the face, lips, or throat, leading to severe difficulty breathing, or a widespread, itchy rash. Adverse effects on adrenal gland function (suppression) are serious and more likely with long-term, extensive, or occluded use.
Population Restrictions Contraindicated (not to be used) in children under 10 years of age. Use in children aged 10 and above must be limited to short durations, typically 3 days, and long-term therapy should be avoided due to the increased risk of systemic absorption. Pregnant or breast-feeding individuals should seek medical advice.
Safety Restrictions Do not apply to the eyes, face, ano-genital areas, or to untreated bacterial, fungal, or viral infections of the skin (e.g., cold sores, impetigo, acne, or rosacea). Use under occlusive dressings (e.g., nappies or airtight plasters) is prohibited as it significantly increases the amount of medicine absorbed.
Exposure-Related Risk Systemic side effects, such as adrenal gland suppression and possible blurred vision, are more likely when the cream is used frequently, over a large area, or for longer than the recommended duration. The product carries a serious fire risk as fabric (clothing, bedding) that has been in contact with the cream burns more easily.

Overdose and Emergency Response

The official regulatory profile for Skincalm overdose is defined by the risk of systemic absorption resulting from excessive or prolonged topical use. This exposure can lead to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, the primary documented manifestation. Officially recognized clinical outcomes of prolonged overdose include signs resembling Cushing's syndrome, hyperglycemia, and glucosuria.

Immediate actions are mandated for two distinct overdose scenarios. If the product is swallowed (acute ingestion), contact Poison Control or local emergency services immediately. If signs of systemic toxicity are observed—such as unusual tiredness, weakness, or increased thirst—users must check with a doctor right away, as these may indicate adrenal gland problems.

Population-specific considerations note that pediatric patients are at higher risk for systemic toxicity, including HPA axis suppression and intracranial hypertension, due to their higher surface area to body weight ratio. Management of HPA suppression involves procedural steps such as drug withdrawal or substitution with a less potent steroid, as no specific antidote is known for this condition. Monitoring for HPA axis suppression may require specific tests, including the ACTH stimulation test, as described in regulatory documentation.

Therapeutic Uses of Skincalm

What Skincalm Treats: Main Uses and Benefits

Skincalm is a therapeutic treatment designed to provide focused, symptomatic relief in specific dermatological contexts, helping patients manage discomfort.

Supportive topical treatments are often utilized to help manage symptoms related to inflammatory or irritative states. This aligns with the therapeutic domains where short-term symptom management is appropriate. Skincalm may be relevant for easing symptoms that create noticeable physiological strain, including redness, heat, swelling, persistent itchiness (pruritus), and extreme dryness (xerosis).

It is considered relevant in clinical settings that involve acute or unstable symptom patterns associated with conditions like eczema and contact dermatitis. Skincalm is applied across domains where additional symptomatic support is needed during flare-up episodes or periods of increased distress. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

“The product may be part of symptomatic management in contexts marked by increased discomfort or tension, supporting the patient during difficult episodes by easing symptoms related to physical discomfort.”

This supportive relief assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Pruritus

Skincalm is used for managing the symptoms of persistent itchiness (pruritus) that can interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia overview

Eligibility and Restrictions for Use

The eligibility for using Skincalm is defined by official regulatory labeling, focusing primarily on patient age, physiological state, and pre-existing conditions.

Contraindications and Absolute Exclusions

Skincalm must not be used by patients with a history of hypersensitivity (allergy) to Hydrocortisone or any other component in the cream. Regulatory documents also contraindicate use in the presence of specific skin conditions, including viral diseases (such as chickenpox or herpes simplex), rosacea, and acne vulgaris.

Age-Related Eligibility and Restrictions

Age Group Eligibility Status (Regulatory Basis)
Children under 2 years Restricted Use: Official labeling instructs patients to ask a doctor before use.
Children (General) Conditional Use: Administration must be limited to the least amount necessary due to a greater risk of systemic toxicity (e.g., HPA axis suppression) compared to adults.

Conditional Use and Cautions

Use is restricted or requires caution in the following populations:

  • Pregnancy and Lactation: Use should only occur if the potential benefit justifies the risk to the fetus or infant, and should be limited to small areas for short periods.
  • Patients with Comorbidities: Caution is required for patients with pre-existing conditions such as Diabetes or Cushing’s syndrome, as systemic absorption may worsen these conditions.
  • Skin Integrity: Application over large surface areas, on broken skin, or under occlusive dressings (including tight-fitting diapers on children) is generally restricted, as this significantly increases the risk of systemic absorption.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Skincalm (topical Hydrocortisone) is primarily defined by a single pharmacokinetic risk related to its metabolism. Since the active ingredient, Hydrocortisone, is metabolized by the CYP3 A4 enzyme, co-administration with other medicines that are potent inhibitors of this enzyme can result in an interaction.

Official Pharmacokinetic Interaction

Element Regulatory Statement
Interacting Medicine Category Potent inhibitors of the CYP3 A4 enzyme
Specific Interacting Agents Ritonavir and Cobicistat
Interaction Outcome Increased systemic exposure of the corticosteroid

Co-administration of the cream with potent CYP3 A4 inhibitors, such as ritonavir and cobicistat, is officially noted to inhibit the clearance of the corticosteroid from the body, leading to an increased concentration systemically. This outcome is officially classified as a pharmacokinetic interaction and is the main documented drug-drug caution for topical corticosteroids.

Interaction-Context Constraints

Constraint Regulatory Note
Contraindications No formally contraindicated medicinal combinations are listed in the regulatory label.
Conditions Increasing Risk The risk of increased systemic exposure is heightened when the cream is applied to a large surface area, when used with occlusive dressings, or in patients with an impaired skin barrier function.
Food/Alcohol/Herbal Products No clinically established or officially documented interactions with food, alcohol, or herbal products are noted in the regulatory labels.

Regulatory documentation confirms that outside of the CYP3 A4 pathway, no other drug, food, or timing-based interactions are known or established for this low-potency topical preparation.

Mechanism of Action

How Skincalm Works

Skincalm is designed to influence core mechanisms at the biological level to modulate dysregulated physiological processes. Its primary action focuses on targeted pharmacodynamic effects within defined cellular pathways.

Key Receptor and Enzyme Modulation

Skincalm acts by engaging defined biological targets, specifically modulating activity within a select receptor or enzyme system. This targeted interaction at the molecular level is used to initiate or suppress early signaling sequences that lead to downstream effects.

Dampening Excessive Signaling Pathways

The drug operates within well-characterized molecular cascades, influencing signal transduction to alter signaling dynamics. This mechanism is primarily applied in systems involving heightened pathway activation to dampen excessive signaling that mediates overactive physiological responses.

Influencing Regulated Physiological States

By modifying early molecular steps and reducing levels or action of excessive mediators, Skincalm engages mechanisms that regulate cellular processes driven by distinct signaling patterns. This targeted mechanistic effect modulates overactive physiological responses, resulting in physiological adjustments that influence the resulting mechanistic outcomes.

Dosage and Administration Information

How to Use Skincalm: Administration Guidelines

Skincalm, a topical hydrocortisone formulation, is intended strictly for dermal application to the affected skin area. The administration of this medicine is based on high-level, short-term usage principles.


Administration Scope

Feature Guideline
Route of administration: Topical (dermal) application only.
Dosing schedule: Apply a thin film of the cream to the affected area. Common strengths include 0.5% and 1%.
Frequency and duration: Application is typically two or three times per day. Treatment is consistently intended for short-term use, often limited to no more than 7 consecutive days for over-the-counter products.

Procedural and Population Constraints

The treatment area must be clean and the cream should be rubbed in gently. Application is strictly for external use only, and contact with the eyes should be avoided.

Occlusion Constraint: The treated skin area must not be covered, bandaged, or wrapped with an occlusive dressing unless expressly instructed by a healthcare provider, as this significantly increases the absorption of the active ingredient.

Pediatric Guidelines: For use on children, administration is limited to the least effective dose for the shortest duration, commonly restricted to no more than seven to ten days. When applied to an infant's diaper area, it is generally advised against the use of tight-fitting diapers or plastic pants to prevent an unintended occlusive effect. If another topical product is also being applied, a separation of at least 10 minutes between applications is recommended.

Recent Clinical Evidence

Skincalm: Overview of Research Evidence

Research into Skincalm (low-potency topical hydrocortisone) is based primarily on Short-Term Randomized Controlled Trials (RCTs) examining its use for mild-to-moderate atopic dermatitis (eczema). These studies randomly assign participants to receive the active medicine or an inactive cream to observe how symptoms change over a defined time interval. Researchers monitored objective measures like the Investigator Global Assessment (IGA) and patient-reported outcomes related to physical discomfort and pruritus (itching). Studies report patterns related to the measured change in symptom severity observed when compared to the inactive cream.


For contact dermatitis and other inflammatory rashes, the research focused on measuring visible signs of inflammation, such as localized redness and swelling, during short, defined treatment courses, typically under 14 days. Evidence for this broader context is rooted in the medicine's classification as an agent for corticosteroid-responsive dermatoses, though specific data remains limited for some narrow applications. Small Randomized Controlled Crossover Trials also evaluated the medicine for managing persistent itchiness (pruritus ani), tracking changes in itch severity using scales like the Visual Analogue Scale (VAS).


The evidence base has key limitations. Follow-up durations were limited, typically lasting only a few weeks, meaning long-term effects are not fully established and data on sustained symptom prevention are scarce. While studies have evaluated its use in children experiencing mild-to-moderate eczema, the data for certain groups remain insufficient, particularly regarding long-term outcomes in older adults or populations with complex comorbidities. The research provides context but does not determine whether an individual will respond similarly when managing chronic, recurring conditions.

Key Studies & References Hydrocortisone Topical Cream: U.S. National Library of Medicine Labeling and Drug Information

Frequently Asked Questions (FAQ)

Common questions about Skincalm (FAQ)


Q: Is Skincalm a type of steroid or immunosuppressant?

Skincalm's active ingredient, hydrocortisone, is classified as a corticosteroid or glucocorticoid. This classification means its main function is to reduce inflammation.

While all glucocorticoids can affect the immune system, the risk of significant systemic effect is low when Skincalm is used as directed for short periods and applied only to the skin, as described in official product information.


Q: How quickly does Skincalm usually start to work?

Studies indicate that relief, particularly of pruritus (itching), has been reported to begin within 24 hours of starting therapy. The full therapeutic effect and overall symptom change are typically measured over the short-term treatment course.


Q: Are there any long-term effects of using Skincalm that people should know about?

According to official product information, Skincalm is intended for short-term use. Prolonged or extensive application is associated with localized skin changes, including skin thinning (atrophy), stretch marks, and the widening of blood vessels.

The likelihood of these local side effects, and the risk of systemic absorption (effects on the rest of the body), is understood to increase with use beyond the recommended duration.


Q: What official body approved Skincalm for its use?

The approval for the use of Hydrocortisone products like Skincalm is granted by the governmental health authority responsible for medicine regulation in the jurisdiction where it is sold. Examples of these authorities include the FDA (U.S.) or the EMA (E.U.). These agencies ensure the medicine meets established safety and quality standards before it is made available to the public.


Q: What happens if I forget to take a dose of Skincalm?

Official patient information describes that if an application is missed, it can be applied as soon as the person remembers. If it is nearly time for the next scheduled application, the recommendation is to skip the missed dose and resume the regular schedule.

Regulatory guidance advises not to double the amount applied to make up for a missed dose.


Q: Is it common to feel tired when starting Skincalm?

Official regulatory summaries include unusual tiredness or weakness as a potential symptom related to the systemic absorption of the active ingredient, which occurs when it enters the body through the skin.

If this effect is experienced, a healthcare professional should be consulted.


Q: What should I do if the side effects of Skincalm bother me?

Official product information advises that if bothersome side effects, such as a worsening skin rash, burning, irritation, or swelling, occur, discontinuation of the medicine may be considered.

Prompt contact with a healthcare professional is necessary to review the symptoms.


Q: Can Skincalm make my skin condition temporarily worse?

Official safety documentation indicates that if your condition worsens or if new symptoms like irritation, swelling, or burning occur after applying Skincalm, this may suggest a local reaction or a change in the underlying skin condition.

Official safety information indicates that if this occurs, product discontinuation and professional medical review are warranted.


Q: Is Skincalm safe for someone who has liver or kidney issues?

Regulatory guidance suggests that systemically absorbed Hydrocortisone is processed by the liver and eliminated by the kidneys.

Official documents advise that caution and medical review are generally warranted for patients with pre-existing conditions, particularly severe kidney impairment, due to potential effects on the body's fluid and electrolyte balance.


Q: What does 'contraindicated' mean in relation to Skincalm?

In regulatory language, a contraindication defines a specific situation or pre-existing health condition where Skincalm must not be used.

This is because using the medicine under these circumstances carries a clear risk of harm or could potentially worsen the existing condition, such as in the presence of certain viral skin infections or known hypersensitivity to the drug.


Q: Is there a generic version of Skincalm available?

The active ingredient in Skincalm is Hydrocortisone. This compound is a widely used generic medicine and is available from various manufacturers both as a generic preparation and under different brand names.


Q: How do I know if Skincalm is the right medicine for my condition?

Regulatory documents state that Skincalm is indicated for relief of the inflammatory and pruritic (itchy) signs of skin conditions that respond to corticosteroids.

To determine if the medicine is appropriate for a specific individual and their condition, the professional judgment of a healthcare provider is required.


Q: Can older adults (seniors) safely use Skincalm?

Official regulatory guidance notes that while studies have not shown major differences in safety or effectiveness in older patients, caution is generally warranted.

This caution reflects the greater likelihood of underlying health conditions or decreased organ function (such as liver, kidney, or heart function) in the elderly population.


Q: What if I have an allergic reaction to Skincalm?

Signs of a severe allergic reaction, such as swelling of the face, lips, or throat, or difficulty breathing (anaphylaxis), are described in official safety documents as very serious, though rare.

If a person experiences these symptoms, official guidance states that the product must be discontinued, and emergency medical assistance should be immediately sought.


Q: What happens if I accidentally take too much Skincalm?

Applying too much Skincalm, using it over a large skin area, or using it for too long increases the risk of systemic side effects, such as effects on the adrenal gland function.

Official guidelines advise that in the case of excessive use or accidental swallowing, a person contact a poison control center or emergency room.


Q: Is Skincalm addictive or habit-forming?

Skincalm is not considered addictive in the traditional sense. However, official regulatory bodies have acknowledged the potential for a reaction upon stopping the medicine that can include intense redness, burning, or stinging, sometimes referred to in patient communities as 'Topical Steroid Withdrawal.'


Q: Is Skincalm considered a newer or older type of treatment?

Skincalm's active ingredient, Hydrocortisone, is a compound that is a synthetic derivative of the body's natural hormone, cortisol.

It is classified as an older, well-established medicine within the corticosteroid class of treatments.


Q: Is it common to feel a stinging or burning sensation when applying Skincalm?

Official product information indicates that stinging, burning, or mild irritation are recognized local side effects, particularly when the medicine is first applied to the skin. These local reactions are often temporary.

How should Skincalm be stored and disposed of?

Official Storage and Disposal Instructions

Storing Skincalm (Hydrocortisone 1% Cream) must strictly follow official regulatory requirements to maintain its stability and ensure safety. The product must be stored below 25°C (77°F) and kept away from excessive heat, dampness, or freezing. Storage in areas like bathrooms or near a sink should be avoided. The medicine carries a labeled shelf-life of 60 months when kept under these conditions.

Child Safety and Disposal

  • Child Safety: It is a mandatory requirement to keep this medicine out of the sight and reach of children.
  • Disposal: Unused or expired Skincalm must not be discarded via household waste or flushed into wastewater. Disposal must be handled by professional means; individuals are required to ask a pharmacist for the proper method to throw away the medicine.

Compliance with these rules ensures the integrity of the product and adherence to environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Skincalm found in:

A-Z Index: